Group 1 - Novartis has agreed to sell its 70.68% stake in Novartis India Ltd. for ₹14.46 billion (approximately $159 million) to a consortium of investors including WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners [1] - The transaction marks the conclusion of a strategic review initiated by Novartis in February 2024 regarding its listed subsidiary [1] - Novartis India Ltd. is primarily responsible for the sales of prescription drugs, generics, and over-the-counter products in the Indian market [1] Group 2 - Following the transaction, Novartis India will advance its business development under new majority ownership [1] - The acquiring consortium has launched a public offer to acquire up to 26% of Novartis India shares at ₹860.84 per share, valuing the offer at approximately ₹5.52 billion [1] - Novartis has clarified that the strategic review does not involve its wholly-owned subsidiary, Novartis Healthcare Pvt. Ltd., which oversees commercial operations in the region [1][2] Group 3 - Prior to the strategic review, Novartis India had signed multiple distribution agreements with local partners, including a collaboration with Dr. Reddy's Laboratories Ltd. to market products such as Voveran and calcium series products in India [1] - The divestiture adjusts the ownership structure of Novartis India while allowing Novartis to retain its infrastructure and research layout in the Indian market [2]

Core Viewpoint - Novartis AG is selling a majority stake in its Indian unit, Novartis India Ltd., as part of a strategic review initiated two years ago, with the sale valued at ₹1,446 crore ($159 million) [1] Group 1: Transaction Details - Novartis will sell its 70.68% stake in Novartis India Ltd. to a consortium consisting of WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners [1] - The buyers have initiated an open offer to acquire up to 26% of Novartis India at ₹860.84 per share, which values the offer at approximately ₹552 crore [2] Group 2: Strategic Review Context - In February 2024, Novartis announced a review of its India-listed unit, which markets prescription drugs, generic, and over-the-counter medicines, excluding its wholly-owned unit Novartis Healthcare Pvt. [3] - Novartis India had previously entered distribution agreements with local partners, including Dr. Reddy's Laboratories Ltd., to market various brands in the Indian market [4]